Dexfenfluramine and appetite in humans - PubMed (original) (raw)
Review
. 1992 Dec:16 Suppl 3:S51-9.
Affiliations
- PMID: 1338323
Review
Dexfenfluramine and appetite in humans
J E Blundell et al. Int J Obes Relat Metab Disord. 1992 Dec.
Abstract
Dexfenfluramine has been demonstrated to produce decreases in daily energy intake varying between 13 and 25% depending on the time for which the drug has been administered. This reduction in energy intake is achieved by a decrease in the size of meals (11-40% depending on the dose) and by a decrease in the frequency of snacks consumed between meals. These objective adjustments are accompanied by a decrease in the level of perceived hunger, particularly apparent in the postprandial period. Taken together these changes can be interpreted as an action of dexfenfluramine to intensify the satiating power of food. This effect is consistent with the proposed role of serotonin systems in the mediation of satiety. The effect of dexfenfluramine on eating parameters leads to an overall modulation of the pattern of eating and the profile of motivation to eat. The reduction in energy intake achieved by this modulation is consistent with the weight losses recorded following several months of treatment. This restraint over the expression of appetite exerted by dexfenfluramine appears to be present even after 12 months of continuous treatment. These demonstrated actions should help overweight people to achieve a better management of their appetite in order to assist weight loss and to prevent weight regain.
Similar articles
- The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks.
Drent ML, Zelissen PM, Koppeschaar HP, Nieuwenhuyzen Kruseman AC, Lutterman JA, van der Veen EA. Drent ML, et al. Int J Obes Relat Metab Disord. 1995 May;19(5):299-304. Int J Obes Relat Metab Disord. 1995. PMID: 7647820 Clinical Trial. - On the mechanism of action of dexfenfluramine: effect on alliesthesia and appetite motivation in lean and obese subjects.
Blundell JE, Hill AJ. Blundell JE, et al. Clin Neuropharmacol. 1988;11 Suppl 1:S121-34. Clin Neuropharmacol. 1988. PMID: 3180107 - Sensitivity of the appetite control system in obese subjects to nutritional and serotoninergic challenges.
Hill AJ, Blundell JE. Hill AJ, et al. Int J Obes. 1990 Mar;14(3):219-33. Int J Obes. 1990. PMID: 2187822 Clinical Trial. - [Dexfenfluramine and feeding behavior. Clinical and pharmacoclinical studies].
Fantino M. Fantino M. Ann Med Interne (Paris). 1989;140 Suppl 1:12-6. Ann Med Interne (Paris). 1989. PMID: 2672935 Review. French. - Serotonin and dietary fat intake: effects of dexfenfluramine.
Blundell JE, Lawton CL. Blundell JE, et al. Metabolism. 1995 Feb;44(2 Suppl 2):33-7. doi: 10.1016/0026-0495(95)90207-4. Metabolism. 1995. PMID: 7869935 Review.
Cited by
- Mutation of the Drosophila melanogaster serotonin transporter dSERT impacts sleep, courtship, and feeding behaviors.
Knapp EM, Kaiser A, Arnold RC, Sampson MM, Ruppert M, Xu L, Anderson MI, Bonanno SL, Scholz H, Donlea JM, Krantz DE. Knapp EM, et al. PLoS Genet. 2022 Nov 21;18(11):e1010289. doi: 10.1371/journal.pgen.1010289. eCollection 2022 Nov. PLoS Genet. 2022. PMID: 36409783 Free PMC article. - Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.
Davis R, Faulds D. Davis R, et al. Drugs. 1996 Nov;52(5):696-724. doi: 10.2165/00003495-199652050-00007. Drugs. 1996. PMID: 9118819 Review.